A Phase III Randomized Double-Blind Active Comparator-Controlled Study

Recruiting

99 years or below

All

Phase 3

1 Location

Brief description of study

The purpose of the study is to compare letermovir to valganciclovir in preventing CMV disease in patients who have received a kidney transplant and are considered to be at high-risk for CMV disease after their transplant. The main study intervention is taking letermovir (or placebo for letermovir) plus valanciclovir (or placebo for valganciclovir) for 28 weeks after kidney transplant, instead of receiving the standard of 6 months valganciclovir post-transplant.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: TBD
Age: 99 years or below
Gender: All

Updated on 13 Feb 2019. Study ID: 829228

Find a site

Your Information has been sent successfully.

Message sent successfully.

We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.

If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.

Send a message

Enter your contact details to connect with study team

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A Phase III Randomized Double-Blind Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of MK-8228 (Letermovir) Versus Valganciclovir for the Prevention of Human Cytomegalovirus (CMV) Disease in Adult Kidney Transplant Recipients

Brief description of study

Eligibility of study

Find a site